Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690011 | 1.00 | ALDH1A1 (0.56) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 | |
| SCHEMBL31067901 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 | |
| SCHEMBL7915675 | 0.79 | ALDH1A1 (0.60) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 | |
| SCHEMBL49213 | 0.79 | HSD17B10 (0.74) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 | |
| SCHEMBL8500339 | 0.77 | HSD17B10 (0.71) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 | |
| SCHEMBL1921580 | 0.77 | HSD17B10 (0.71) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 | |
| Ammonia Solution, Strong SCHEMBL11586421 | 0.77 | HSD17B10 (0.71) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 | |
| SCHEMBL8682861 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 | |
| SCHEMBL7483801 | 0.75 | ALDH1A1 (0.56) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 | |
| SCHEMBL9370129 | 0.75 | ALDH1A1 (0.56) | ALDH1A1HSD17B10TSHRHPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907350-B | Nitrogen-containing condensed ring compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-111526877-B | Compounds and compositions for IRE1 inhibition | 奥普提卡拉公司 | 2023-08-25 | — | — | CN | disclosed |
| US-11649237-B2 | Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition | OPTIKIRA LLC (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-114222732-B | Uric acid excretion promoter, synthesis method thereof and application thereof in medicine | 南京明德新药研发有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114349684-B | Synthetic method of benzo [ c, d ] indole imine derivative | 西南林业大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-114907350-A | Nitrogen-containing condensed ring compounds, preparation method and application | 上海凌达生物医药有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114349684-A | Synthetic method of benzo [ c, d ] indole imine derivative | 西南林业大学 | 2022-04-15 | — | — | CN | disclosed |
| CN-114222732-A | Uric acid excretion promoter, synthesis method thereof and application thereof in medicine | 南京明德新药研发有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109912432-B | Aryne alkynyl 1-naphthylamine fluorescent compound, preparation method and application | 湖南大学 | 2021-10-08 | — | — | CN | disclosed |
| US-6492529-B1 | PHARMACEUTIC COMPOSITIONS FOR TREATING DISEASES OR PATHOLOGICAL CONDITIONS INVOLVING INFLAMMATION SUCH AS CHRONIC INFLAMMATORY DISEASES. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020103401-A1 | Process for the production of 1,5-naphthalenediamine | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-01 | — | — | US | disclosed |
| US-20020065285-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | HICKEY EUGENE R (US) | 2002-05-30 | — | — | US | disclosed |
| US-20020058678-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | CIRILLO PIER F (US) | 2002-05-16 | — | — | US | disclosed |
| US-6372773-B1 | TREATMENT OF INFLAMMATION, ARTHRITIS WITH UREA OR THIOUREA HETEROCYCLES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-04-16 | — | — | US | disclosed |
| US-6333325-B1 | ADMINISTERING PYRAZOLE DERIVATIVE OF UREA OR THIOUREA FOR THERAPY OF CYTOKINE MEDIATED DISEASE SUCH AS ACTUATE AND CHRONIC PAIN, CONTACT DERMATITIS, ATHEROSCLEROSIS, GLOMERULONEPHRITIS, REPERFUSION INJURY, BONE RESORPTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-25 | — | — | US | disclosed |
| US-6329415-B1 | INHIBIT RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-6319921-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, CROHN'S DISEASE ULCERATIVE COLITIS, PSORIASIS, GRAFT VERSUS HOST DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS AND DIABETES | BOERHINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-20 | — | — | US | disclosed |
| EP-1147104-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043384-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103401-A1 | Process for the production of 1,5-naphthalenediamine | BBOX1, CYP4B1, NAT1 | ALDH1A1 455/4885HSD17B10 244/4885TSHR 3810/4885 |
| US-11649237-B2 | Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition | XBP1, HSPA5, ERN1 | ALDH1A1 1720/4885HSD17B10 3311/4885TSHR 3585/4885 |
| US-20020065285-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | FPR1, AHR, FPR2 | ALDH1A1 294/4885HSD17B10 1510/4885TSHR 3935/4885 |
| US-20020058678-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | FPR1, AHR, FPR2 | ALDH1A1 294/4885HSD17B10 1510/4885TSHR 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.